Enhancing pediatric access to cell and gene therapies

Area of Science:

• Biotechnology
• Pediatric Medicine
• Drug Development

Background:

• Cell and gene therapies (CGTs) show promise for pediatric diseases.
• Traditional biopharmaceutical models struggle with small pediatric market sizes, leading to market failure.
• High manufacturing costs, regulatory hurdles, and misaligned licensing practices impede pediatric CGT development.

Purpose of the Study:

• To identify key factors contributing to the market failure of pediatric CGTs.
• To propose a novel solution to address the development and commercialization gap for pediatric CGTs.
• To enhance access to life-saving CGT treatments for children.

Main Methods:

• Perspective analysis of current biopharmaceutical development models.
• Identification of challenges in pediatric CGT development and commercialization.
• Proposal of a new organizational structure: Pediatric Advanced Medicines Biotech.

Main Results:

• The traditional model presents significant barriers to pediatric CGT development.
• A new entity can bridge the 'valley of death' for pediatric CGTs.
• Collaboration between academia, manufacturing, and regulatory bodies is crucial.

Conclusions:

• A dedicated entity, Pediatric Advanced Medicines Biotech, is proposed to overcome market failures.
• This entity would facilitate late-stage development and commercialization outside traditional models.
• The initiative aims to increase access to innovative CGTs for pediatric patients in the US.